Carta al Director
Seguridad y efectividad de la dapagliflozina con otro inhibidor del SGLT-2: ¿qué decisión tomar?
Security and effectivity from the dapagliflozim with other inhibitor of the SGLT-2: What decision to take?
H. Mejía-Zambrano
Escuela Profesional de Medicina Humana, Universidad Privada San Juan Bautista, Lima, Perú
Leído
21539
Vecesse ha leído el artículo
899
Total PDF
20640
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 32 | 12 | 44 |
| 2025 11 | 394 | 69 | 463 |
| 2025 10 | 404 | 51 | 455 |
| 2025 9 | 383 | 55 | 438 |
| 2025 8 | 338 | 30 | 368 |
| 2025 7 | 364 | 31 | 395 |
| 2025 6 | 370 | 17 | 387 |
| 2025 5 | 457 | 37 | 494 |
| 2025 4 | 734 | 47 | 781 |
| 2025 3 | 945 | 36 | 981 |
| 2025 2 | 1036 | 24 | 1060 |
| 2025 1 | 992 | 27 | 1019 |
| 2024 12 | 1410 | 23 | 1433 |
| 2024 11 | 1395 | 35 | 1430 |
| 2024 10 | 829 | 37 | 866 |
| 2024 9 | 673 | 26 | 699 |
| 2024 8 | 743 | 34 | 777 |
| 2024 7 | 694 | 17 | 711 |
| 2024 6 | 682 | 15 | 697 |
| 2024 5 | 597 | 22 | 619 |
| 2024 4 | 568 | 25 | 593 |
| 2024 3 | 681 | 17 | 698 |
| 2024 2 | 699 | 5 | 704 |
| 2024 1 | 946 | 17 | 963 |
| 2023 12 | 653 | 11 | 664 |
| 2023 11 | 644 | 24 | 668 |
| 2023 10 | 656 | 13 | 669 |
| 2023 9 | 548 | 17 | 565 |
| 2023 8 | 418 | 14 | 432 |
| 2023 7 | 344 | 6 | 350 |
| 2023 6 | 259 | 17 | 276 |
| 2023 5 | 314 | 4 | 318 |
| 2023 4 | 134 | 1 | 135 |
| 2023 3 | 21 | 0 | 21 |
| 2023 2 | 11 | 4 | 15 |
| 2022 1 | 24 | 5 | 29 |
| 2022 12 | 25 | 11 | 36 |
| 2022 11 | 28 | 7 | 35 |
| 2022 10 | 32 | 12 | 44 |
| 2022 9 | 14 | 2 | 16 |
| 2022 8 | 4 | 2 | 6 |
| 2022 7 | 15 | 0 | 15 |
| 2022 6 | 24 | 4 | 28 |
| 2022 5 | 36 | 4 | 40 |
| 2022 4 | 70 | 6 | 76 |
| 2022 3 | 0 | 26 | 26 |
Mostrar todo
